Vertex Pharmaceuticals Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 03/22/2023
Vertex Pharmaceuticals Inc Stock Forecast and Price Target
The average target price for Vertex Pharmaceuticals Inc's stock set by eighteen renowned analysts in recent months is $326.00, representing a potential upside of approximately 7.71% from its last closing price if met by 2024. This estimation is based on a high estimate of $440.00 and a low estimate of $280.00. Even if you are not interested in VRTX stock, it is still imperative to be aware of its competitors.
7.71% Upside
Vertex Pharmaceuticals Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Price for Vertex Pharmaceuticals Inc has grown by 144.28%, going from $148.28 to $362.22. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $432.60 – an increase of 19.43%. Over the next eight years, experts anticipate that Fair Value growth for Vertex Pharmaceuticals Inc will be 74.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$153.96 | Buy/Sell | $181.05 | 17.24% |
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$331.08 | Buy/Sell | $333.19 | 20.82% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$40.66 | Buy/Sell | $53.97 | 29.49% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$105.62 | Buy/Sell | $99.57 | 11.72% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$67.52 | Buy/Sell | $80.99 | 22.93% |
Vertex Pharmaceuticals Inc Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Revenue for Vertex Pharmaceuticals Inc has grown by 81.95%, going from $4.16B to $7.57B. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach $9.24B – an increase of 21.94%. Over the next eight years, experts anticipate that Revenue growth for Vertex Pharmaceuticals Inc will be 69.63%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$759.81 | Buy/Sell | $796.73 | 2.92% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$166.35 | Buy/Sell | $209.70 | 23.23% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$39.62 | Buy/Sell | $60.73 | 46.39% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$190.34 | Buy/Sell | $244.18 | 31.87% |
| VTRS Stock Forecast | Viatris | Hold |
8
|
$9.44 | Buy/Sell | $13.70 | 43.01% |
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$222.34 | Buy/Sell | $280.69 | 32.68% |
Vertex Pharmaceuticals Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Vertex Pharmaceuticals Inc's Free Cash Flow has grown, increasing from $1.49B to $2.41B – an increase of 61.22%. For next year, the 7 analysts predict Free Cash Flow of $3.84B, which would mean an increase of 59.44%. Over the next eight years, the pros' prediction is Free Cash Flowof $6.40B, which would mean a eight-year growth forecast of 165.57%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$66.78 | Buy/Sell | $83.92 | 9.31% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$35.62 | Buy/Sell | $52.42 | 40.37% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$36.17 | Buy/Sell | $62.67 | 65.88% |
Vertex Pharmaceuticals Inc Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Vertex Pharmaceuticals Inc's Net Income has increased by 99.02%, going from $1.18B to $2.34B. In the next year, analysts are expecting an increase in Net Income, predicting it will reach $4.05B – an increase of 73.10%. The Vertex Pharmaceuticals Inc forecast is for Net Income to reach $6.01B or grow by 156.57%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$127.30 | Buy/Sell | $163.67 | 28.83% |
| NEOG Stock Forecast | Neogen | Hold |
16
|
$18.91 | Buy/Sell | $37.00 | 34.85% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$21.25 | Buy/Sell | $0.00 | 38.82% |
Vertex Pharmaceuticals Inc EBITDA Forecast for 2023 - 2025 - 2030
Vertex Pharmaceuticals Inc's EBITDA has increased by 121.91% In the last two years, going from $1.31B to $2.90B. In the next year, analysts expect EBITDA to reach $5.57B – an increase of 91.63%. For the next eight years, the forecast is for EBITDA to grow by 89.66%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$14.91 | Buy/Sell | $73.38 | 27.43% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£179.50 | Buy/Sell | £3.79 | -97.36% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$40.28 | Buy/Sell | $79.67 | 93.64% |
Vertex Pharmaceuticals Inc EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Vertex Pharmaceuticals Inc's EBIT has grown, increasing from $1.20B to $2.78B – a growth of 131.20%. The next year looks promising for Vertex Pharmaceuticals Inc, with analysts predicting EBIT of $5.07B – an increase of 82.50%. Over the next eight years, experts anticipate that Vertex Pharmaceuticals Inc's EBIT will grow at a rate of 162.88%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$36.99 | Buy/Sell | $41.00 | 18.95% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$10.59 | Buy/Sell | $12.60 | 18.04% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$36.70 | Buy/Sell | $35.50 | -7.36% |
Vertex Pharmaceuticals Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, EPS for Vertex Pharmaceuticals Inc has grown by 144.28%, going from $5.33 to $13.02. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $15.55 – an increase of 19.43%. Over the next eight years, experts anticipate that EPS growth for Vertex Pharmaceuticals Inc will be 74.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$71.18 | Buy/Sell | $195.43 | 122.67% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$245.62 | Buy/Sell | $170.08 | -28.75% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$61.15 | Buy/Sell | $104.00 | -6.79% |
Site Navigation
.jpg)